Regional People with overweight, all classes of obesity, and T2D spotlighting the frequent concurrence of the two conditions Obesity x T2D overlap Wegovy and Zepbound are not FDA-approved to treat type 2 diabetes, but in clinical trials, in addition to losing weight, patients saw improvements in blood glucose levels
Mean body weights decreases of 12.7% over placebo were seen after 68 weeks in Rybelsus treated patients
One study explored mechanistic associations between GLP-1 functioning and mood disorders in humans: a post-mortem investigation showed that, compared with healthy controls, patients who had been diagnosed with mood disorders had lower expression of the gene encoding for GLP-1R in the dorso-lateral prefrontal cortex and the hippocampus, whereas this association was not observed in the brain tissue of people with schizophrenia 176
This includes 6% of adults who say they are currently taking one of these drugs, which include Ozempic, Wegovy and MounjaroThe shares of adults who report ever taking these drugs is highest among people with diabetes (43%), followed by those with heart disease (26%) and those who have obesity or overweight (22%), the poll finds